|
Summary Information: Allogene Therapeutics Inc. Common Stock NASDAQ:ALLO |
  admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
__The following are links to various summary and news pages for __Allogene Therapeutics Inc. Common Stock [ ALLO ]. __Note: Some Links might not have information for the company. |
|